Technology
Health
Biotechnology

Aimmune Therapeutics

$22.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.64 (2.94%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AIMT and other stocks, options, ETFs, and crypto commission-free!

About AIMT

Aimmune Therapeutics, Inc. Common Stock, also called Aimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Read More Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Employees
215
Headquarters
Brisbane, California
Founded
2011
Market Cap
1.41B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
708.36K
High Today
$22.47
Low Today
$21.81
Open Price
$21.89
Volume
718.62K
52 Week High
$36.12
52 Week Low
$16.95

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Research And Development
Food

AIMT News

ReutersAug 9

Edited Transcript of AIMT earnings conference call or presentation 8-Aug-19 8:30pm GMT

34

AIMT Earnings

-$1.01
-$0.91
-$0.81
-$0.71
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.94 per share
Actual
-$1.01 per share

More AIMT News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.